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Abstract 
Prosthetic joint infection usually requires combined medical and surgical therapy. While revision surgery 
is widely considered to be the gold standard surgical procedure, debridement, antibiotics and irrigation 
with implant retention is a very appealing alternative.  
There is however great controversy regarding its real worth with success rates ranging from 0% to over 
90%. A number of different patient and host related variables as well as specific aspects of surgical and 
medical management have been described as relevant for the final outcome. 
Along this paper, the authors will provide the readers with a critical narrative review of the currently 
available literature while trying to provide concise and practical treatment recommendations regarding 
adequate patient selection criteria, proper surgical technique and optimal antibiotic therapy. 
Key words: Prosthetic Joint Infection; Irrigation and Debridement; Implant retention; Total Knee Arthroplasty, 
Total Hip Arthroplasty; Complications 
Introduction 
Debridement, Antibiotics and Irrigation with 
implant Retention (DAIR) is an appealing treatment 
alternative for prosthetic joint infections (PJI). It is less 
demanding than revision surgery both for the surgeon 
and the patient. It is less time consuming and 
technically easier to perform than revision surgery 
and it represents a reduced physiologic insult making 
it easier to recover from.  
It has been shown that successful DAIR 
procedures lead to equivalent outcomes to uninfected 
controls with regards to function and quality of life[1, 
2]. However, patients who have undergone DAIR and 
failed, often undergo multiple subsequent surgical 
procedures adding morbidity and cost to the process. 
Moreover, some studies show poor results of 
two-stage exchange after failed initial DAIR treatment 
thus recommending caution in its use[3, 4]. 
It is not possible to discuss the nuances 
surrounding DAIR for PJI treatment without a prior 
acknowledgment of the microbial biofilm paradigm. 
Ever since the original work by Gristina & 
Costerton[5], a considerable amount of research has 
supported this concept[6]. Biofilms are highly 
structured usually adherent communities of microbial 
cells (of one or several different species) that express 
different phenotypes than its planktonic counterparts. 
They further produce extracellular matrices that 
surround them allowing for cell-to-cell communi-
cation and creating a favorable environment that 
protects the bacteria against the host immune system 
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and most antibiotics although the exact mechanisms 
of such resistance are not fully understood[7, 8].  
Currently, there is extensive controversy in the 
literature regarding the real worth of DAIR 
procedures with success rates ranging from 0% to 
over 90%, and averaging at around 50%[9-11]. There 
are a lot of variables possibly contributing to this wide 
range of reported success rate. The goal of this review 
is to make a critical appraisal of currently available 
knowledge with a special emphasis on conceivable 
selection criteria and practical treatment 
recommendations. 
Indications and Risk Factors for Failure 
Despite the wide variability of recommendations 
present in the literature, it is indisputable that such an 
attempt should only be made with a curative intent 
when facing a well-fixed, well positioned and stable 
prosthesis (i.e. one worth saving) and when there is a 
good soft tissue envelope to cover the prosthesis. 
Several variables have been implicated in the 
likelihood of success of this procedure. Some of them 
such as the actual technique of the procedure and the 
antibiotic regimen are under the direct control of the 
medical team, others such as time since presentation, 
host medical status or even the causative pathogen are 
not, but may serve as selection criteria to find the best 
indication for treatment with implant retention. 
Duration of Symptoms 
Duration of symptoms is a major factor 
implicated in the prognosis of DAIR. It is important to 
emphasize the difference between duration of 
symptoms (i.e. time since infection manifests itself 
and treatment) and the “joint age” (or time from 
implant/index surgery to presentation). In fact, 
successful outcomes are possible in acute 
postoperative but also late acute hematogenous 
infections although some papers seem to point to a 
less favorable scenario in the latter [12-15]. In other 
words, it would seem duration of infection and not 
“joint age” is the decisive factor. The problem in 
clinical practice is how to be sure that a hematogenous 
infection is really an acute infection and not an 
exacerbation of a chronic infection. In fact, not all 
patients report long lasting symptoms prior to their 
presentation with a chronic infection and this may be 
the explanation for less favorable outcomes 
sometimes found in late acute hematogenous PJI. 
Despite the large amount of evidence describing 
the importance of short duration of symptoms, there 
are many discrepancies concerning the best threshold 
for optimal outcomes (see Table 1). Still, the three and 
four weeks limit for hematogenous and post- 
operative infections respectively that was proposed 
by Zimmerli et al.[16] in their original treatment 
algorithm is widely adopted and finds support in the 
current literature [17-24]. 
An international consensus meeting (ICM) 
suggested DAIR could be performed in early 
postoperative infections that occur within 3 months of 
index primary arthroplasty or in late hematogenous 
infection that occur within 3 weeks of an inciting 
event with less than 3 weeks of symptoms in either 
case[25]. Although such a time-frame is controversial, 
there is some evidence suggesting it’s merit. Although 
Grammatopoulos et al. [14] did find significantly 
greater chances to eradicate PJI if DAIR was 
undertaken within 6 weeks from the index procedure, 
good PJI eradication was seen even if DAIR was 
undertaken after 6 (78%) or even 13 weeks (83%). 
 
Table 1. Summary of selected findings that increase risk of failure after DAIR 
 Study details Factors increasing failure 
Joint(s) Country of Origin Success Rate Duration of Symptoms Microorganism(s) Host Status 
Byren et al.[18] 2009 52 THA + 51 
TKA + 9 
other joints 
UK 81% >14 days from 
presentation to 
debridement 
S. aureus PJI 
 
Presence of co-morbidity 
Azzam et al.[12] 2010 53 THA + 53 
TKA 
USA 44% Duration of symptoms 
failed to predict outcome 
Staphylococci PJI; frank 
purulence 
ASA score III/IV 
Peel et al.[34] 2012 118 THA + 
29 TKA 
Australia 71% Only included PJI within 
90 days of implantation 
Gram negative PJI Previous septic exchange; hypotension at 
presentation; 
Buller et al.[17] 2012 62 THA + 
247 TKA 
USA 52% >21 days duration of 
symptoms 
Staphylococci PJI; VR 
Enterococci 
Previous joint infection; higher ESR at 
presentation; 
Kuiper et al.[21] 2013 62 THA + 29 
TKA 
Netherlands 66% > 7 days before the start 
of treatment 
CoN Staphylococci PJI Rheumatoid Arthritis; ESR>60mm/h at 
presentation 
Fehring et al.[20] 2013 40 THA + 46 
TKA 
USA 47% 31-90 days worse than 
<30 days (joint age) 
Type of microorganism 
failed to predict outcome 
Charlson Comorbidity Index failed to 
predict outcome 
Tornero et al.[22] 2015 85 THA + 
137 TKA 
Spain 77% Only included PJI with 
duration of symptoms 
<21 days 
All cultures positive 
during debridement 
Chronic renal failure; liver cirrhosis; 
revision surgery or cemented prosthesis; 
CRP >11.5mg/dL; (KLIC score) 
Grammatopoulos et 
al.[14] 2017 
122 THA UK 85% > 6 weeks after index 
procedure 
Type of microorganism 
failed to predict outcome 
Higher KLIC score 
DAIR -Debridement Antibiotics and Irrigation with implant Retention; TKA – Total knee arthroplasty; THA –Total hip arthroplasty; UK – United Kingdom; USA – United 
States of America; PJI – Prosthetic Joint Infection; VR – Vancomycin-resistant; CoN – coagulase negative; ASA – American Society of Anesthesiologists; ESR - Erythrocyte 
sedimentation rate; CRP – C-reactive protein 
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Although time does matter for biofilm 
formation, DAIR should not be viewed as an 
emergency procedure except in patients with overt 
generalized sepsis. Efforts should be made to 
optimize the patient’s comorbidities and whenever 
possible the procedure should be performed by an 
experienced septic surgeon. 
Type of Microorganism 
Although it is of great consequence, specific 
information about the infecting microorganism(s) and 
its antibiotic susceptibility is frequently not fully 
known when choosing to perform surgery. 
Indeed, staphylococci infections have been 
frequently implicated in unfavorable results after 
DAIR[12, 17, 18, 26, 27]. Methicillin-resistant S. aureus 
(MRSA) specifically, are traditionally considered to be 
a major risk for failure of debridement with 
component retention even in acute infections[28-30]. 
Bradbury et al.[30] have even proposed that if 
MRSA is encountered, subsequent treatment with 
exchange arthroplasty should be considered. Joulie et 
al.[31] analyzed which variables were associated with 
treatment failure in 93 PJI caused by S. aureus. 
Although they found that exchange arthroplasty 
offered a better probability of success than 
debridement alone, they did not find the healing rate 
to be influenced by methicillin resistance[31]. In a 
more recent large retrospective, multicenter, 
observational study of cases of S. aureus PJI that were 
managed with DAIR, the authors found no difference 
in failure rates in MRSA compared to methicillin 
sensitive cases[32]. Nevertheless, both these papers 
showed DAIR was able to save only about 55-57% of 
S. aureus infections[31, 32]. 
Gram negative microorganisms are also a classic 
concern as they have traditionally been implicated in 
worse outcomes with implant retention surgery[33, 
34]. Nevertheless, it seems that if fundamental 
principles such as short duration of symptoms and 
anti-biofilm antibiotic therapy are upheld, success of 
DAIR procedure can be just as good in this group of 
patients[35-38]. The key problem in managing Gram 
negative PJI is the growing antibiotic resistance 
pattern, especially in the Middle East and Asia as well 
as in the European Mediterranean region[39, 40]. It 
has been shown that the prognosis after DAIR is 
dramatically decreased when fluoroquinolone 
resistance is found[36]. Furthermore, even more 
serious problems such as combined resistance to 
third-generation cephalosporins, fluoroquinolones 
and aminoglycosides are often encountered, greatly 
reducing antibiotic treatment alternatives[39]. 
Carbapenemase-producing Enterobacteriaceae are also 
on the horizon and have already been implicated in 
PJI with dire consequences[41]. 
Enterococcus sp. Infections, although uncommon, 
are also of special concern as they are implicated in 
poor outcomes with overall success rates of around 
50%[42-44]. This is particularly true when enterococci 
infection occurs in a polymicrobial setting or exhibits 
vancomycin resistance[17, 42]. A major European 
multicenter study including data from 18 hospitals of 
six different countries focused exclusively on PJI due 
to Enterococcus sp.[44]. They found an overall success 
rate of 56% (100/178) among patients with at least one 
year follow-up after surgery. Implant removal 
showed a higher remission rate than DAIR but this 
reached statistical significance only in those patients 
with more than two years from arthroplasty to 
infection[44]. A recent American multicenter study 
confirms these findings as their overall success rate 
was also low at 52% (45/87)[42]. In this study, success 
rate after DAIR was only 39% (13/33) which was 
significantly lower than results after two-stage 
exchange. Despite that finding, it has been shown that 
a standardized DAIR protocol for treatment of early 
infections can lead to slightly superior results. Duijf et 
al.[45] reported on 44 patients with early Enterococci 
infections (35 polymicrobial). Debridement was 
performed at an average of 15 days after the index 
implantation and patients were treated with 
teicoplanin, rifampicin, vancomycin or amoxicillin or 
a combination of these antibiotics for three months 
postoperatively. The prosthesis could successfully be 
retained in 29 patients (66%) which is, nevertheless, 
worse than with other microorganisms[45].  
Streptococcal infections on the other hand have 
classically shown a more favorable prognosis[14, 26, 
46]. Still, a recent retrospective, observational, 
multicenter, international study that presents the 
largest series of streptococcal PJI managed by DAIR 
with 462 cases, showed a worse prognosis than 
previously reported[47]. However, given the nature of 
the study design and according to the authors own 
admission the criteria for ideal case selection were not 
strictly met by many patients, and the decision to 
undergo DAIR was taken by individual medical 
group on a case by case basis[47]. 
Depending on the specific microorganisms 
involved, polymicrobial infections potentially 
accumulate many of the limitations aforementioned 
and it is natural that they are often implicated in 
limited success rates after DAIR[48, 49].  
Technical Aspects of the Procedure (including 
Mobile Parts Exchange) 
The main goal of surgical debridement is to 
lower the bacterial load within the joint as much as 
possible. In that regard, debridement must be 
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thorough and meticulous and all devitalized tissues 
must be excised. This is a major variable that is not 
possible to accurately assess when reviewing the 
results in the literature.  
Despite the wide range of suggestions regarding 
the best way to perform a DAIR procedure, common 
ground has been reached as to what constitutes a 
favorable debridement[25]. After preoperative 
optimization of the patient has been achieved, good 
visualization and thorough debridement should be 
performed, multiple culture samples should be 
obtained before copious irrigation (6 to 9 L) of the 
joint. Even when choosing to perform a DAIR, 
patients should be advised that the prosthesis may 
still need to be explanted if indicated (e.g. if it is found 
to be loose).  
Mobile parts exchange seems to be an important 
factor for success. Naturally, removing mobile parts 
and replacing them by new ones removes associated 
bacterial biofilm, allows access to parts of the joint 
that are otherwise inaccessible and it allows for 
removal of slime from the undersurface of such 
components, leading to better reduction of bacterial 
load. Polyethylene exchange is widely recommended 
and there seems to be enough evidence of its 
beneficial impact on outcome[13, 16, 17, 19, 21, 23, 25, 
36, 50-61]. In a massive retrospective study including 
over 16,600 PJI, the authors tried to determine risk 
factors for reinfection after treatment of infected TKA 
in the United States[52]. They found that patients who 
underwent DAIR as a first-line treatment had the 
highest risk of reinfection, compared to one- and 
two-stage revision surgery or amputation[52]. More 
interestingly, they found that DAIR with liner 
exchange had significantly reduced risk of reinfection 
even after adjusting for all other available 
variables[52]. Considering all of the above premises, it 
is natural to assume that arthroscopic debridement 
will not suffice. Indeed, even when a posterior portal 
is routinely used to enable debridement of the 
posterior compartment of the knee, this approach is 
not as effective as an open debridement[18, 62, 63].  
Adjuvant(s) of Debridement 
Although they should not be considered 
surrogates for adequate surgical debridement, some 
adjuvant therapies have been advocated as useful 
during the procedure. By far the most commonly used 
is to irrigate the joint with copious amounts of normal 
saline. Although there is the concern that 
high-pressure pulsatile lavage systems may cause 
iatrogenic bacterial seeding into deeper tissue 
layers[64], both low-pressure or high-pressure lavage 
can be used and no significant difference as been 
shown to exist in clinical practice[65]. Some authors 
argue that adding some kind of chemical to the 
irrigation liquid could help in reducing bacterial load.  
In that regard, detergents, antiseptics or even 
antibiotics have been proposed but there is very 
limited evidence of its efficacy in clinical practice and 
most findings originate from in vitro studies. Simply 
adding antibiotics to the lavage fluid, as appealing as 
it may appear, has been shown to be no better than 
saline alone[66, 67]. In light of our current knowledge 
about the pathogenesis of PJI, it is natural to expect 
that some kind of "anti-biofilm” agent would perform 
better. In fact, there is evidence that detergents such as 
castile soap or benzalkonium chloride are more 
effective in disrupting biofilm from metal surfaces 
than saline alone[66, 68]. More recently, chlorhexidine 
gluconate scrub (antiseptic and detergent) was shown 
to be the most effective option at decreasing bacterial 
colony counts when compared to normal saline, 
povidone iodine scrub or castile soap[69, 70]. An 
interesting alternative may be acetic acid, commonly 
known as vinegar. It has been shown in vitro to be 
highly effective against both Gram positive and Gram 
negative biofilms[71]. There is also limited clinical 
evidence of the efficacy and safety profile of a 20 
minutes’ soak of 3% acetic acid solution in the 
debridement of infected TKA[72]. 
A different approach is to try and complement 
surgical debridement by delivering local antibiotics in 
extremely high concentrations that are able to help 
eradicate biofilm remnants. Two different ways of 
achieving this goal have been pursued although there 
is insufficient evidence to definitively support the use 
of either until now. Direct continuous intra-articular 
delivery of antibiotics into the joint was initially 
promoted by Whiteside as an additional treatment in 
exchange revision surgery both for knee and 
hips[73-75]. Fukugawa et al.[58] were the first to 
apply this concept after DAIR. They reported on a 
small series of six infected primary TKA, one revision 
TKA and five tumor mega-prosthesis. There were 
four recurrences, all of them occurring in the 
mega-prosthesis group[58]. There are some potential 
concerns associated with this practice, including drug 
reactions or possible re-infection through the 
catheters used to infuse the antibiotic and the need for 
an additional surgery (to remove the Hickman 
catheter necessary for the intra-articular infusion) and 
the available evidence is not enough to state that 
intra-articular delivery of antibiotics into the joint is 
an independent success factor. 
Another way to deliver local antibiotics that has 
been explored, is to use some kind of 
antibiotic-impregnated carrier (PMMA beads, calcium 
sulphate pellets, collagen fleece, etc.). Antibiotic 
impregnated PMMA beads have a long tradition in 
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bone septic surgery and there are some papers 
exploring its use after DAIR in total joint 
infections[19, 21, 59, 76]. They do however force a 
second surgery for its removal and this has moved the 
focus on to resorbable material such as collagen fleece 
or calcium sulphate pellets[21, 59, 76]. Although small 
series have shown encouraging results, there are no 
randomized, controlled studies to clearly demonstrate 
that the use of these materials enhances the outcome 
of a properly performed procedure. Furthermore, 
resorbable antibiotic carriers are not without 
problems such as increased cost, local reactions and 
increased/persistent wound drainage. 
Antibiotic Treatment 
Following adequate debridement, correct 
antibiotic therapy is critical in achieving infection 
eradication. Most of the times, DAIR procedures will 
take place without previous knowledge of the 
responsible pathogen and effective empiric antibiotic 
therapy must be initiated while waiting for 
intraoperative culture results. 
Initial therapy 
In the early phase of acute PJI, planktonic 
bacteria predominate and so treatment usually starts 
with intravenous (IV) therapy. After the initial 
debulking of bacterial load caused by surgery and IV 
antibiotics the switch to regimens with high oral 
bioavailability and anti-biofilm activity can be made 
thus avoiding prolonged hospital stay and related 
complications. Traditionally, 2- 6 weeks of 
intravenous antimicrobial therapy has been 
recommended[24] but there is growing evidence that 
shortening IV therapy before switching to oral 
therapy is probably not detrimental[77]. 
Exact empirical antibiotic regimens must be 
nation or institution specific in accordance with local 
microbial flora antibiotic susceptibility patterns. As 
soon as definitive microbiology results are available, 
antibiotic therapy is deescalated according to isolated 
pathogen(s) and antibiotic susceptibility pattern.  
Continuation therapy 
The heterogeneous nature of PJI concerning both 
the microorganisms and the host, results in a huge 
diversity of clinical scenarios that make it impossible 
to offer universal solutions. Every case must be 
considered on an individual basis and multidisci-
plinary consultation including infectious diseases 
specialists is critical. There are however some helpful 
guidelines available for consultation[16, 24].  
Notwithstanding, antibiotic therapy after DAIR 
procedures holds some peculiarities that must be 
observed. Unlike revision surgery where the implant 
is removed, it is natural to expect the presence of 
biofilm remnants in the prosthesis after surgical 
debridement. As such, selected antibiotics should 
ideally have anti-biofilm activity. In this regard, ever 
since the pioneer work by Zimmerli[78] et al., 
rifampicin has gained an indisputable role in 
biofilm-related staphylococci infections[13, 16, 51, 60, 
61, 77, 79-81]. Interestingly, it has also been suggested 
that rifampicin in combination with other antibiotics 
may also lead to lower rate of failure in early 
Enterococcus sp. infections treated with DAIR[44]. It is 
important to stress that, because bacteria rapidly 
develop antimicrobial resistance, rifampicin should 
never be administered alone but rather in 
combination therapy[16]. Plus, it should only be used 
after the bulk of bacterial load has been eliminated 
and never in persistently draining wounds[82]. 
Acherman et al.[82] have found that rifampicin 
therapy with inadequate surgical debridement or less 
than two weeks of intravenous treatment was 
independently associated with emergence of 
rifampicin resistance.  
An analogous declaration of importance can be 
made regarding the use of quinolones in Gram 
negative (GN) infections. There is good evidence to 
recommend the use of quinolones when facing 
adequately sensitive GN microorganisms[35, 36, 77, 
83]. In a recent large multicenter study including 242 
Gram negative PJI, ciprofloxacin therapy exhibited an 
independent protective effect[36]. In patients with 
ciprofloxacin-susceptible GN-PJI treated with 
ciprofloxacin, success was 79% (98/124). In 
ciprofloxacin-resistant cases, the efficacy of DAIR 
management was at 41% (14/34). In those with 
susceptible isolates not treated with ciprofloxacin 
success rate was similar at 40% (6/15), suggesting lack 
of ciprofloxacin use and not resistance pattern is 
responsible for the negative impact. The effectiveness 
of ciprofloxacin in these patients is probably 
attributable to its acceptable oral bioavailability, 
optimal diffusion into synovial fluid and bone, and 
activity against biofilm[84]. 
Correct antibiotic regimen is a critical part of 
therapy. A very recent paper by Tornero et al.[77] 
confirms that incorrect antibiotic selection is the most 
important predictor of late failure after DAIR. In their 
study of 143 patients, antibiotic treatment was 
categorized as optimal if it included a combination of 
rifampicin plus rifampicin-independent antibiotic 
(levofloxacin, ciprofloxacin or amoxicillin) or 
monotherapy without rifampicin for Gram positives 
and when it included a fluoroquinolone for Gram 
negatives. It was found to be suboptimal if it included 
a combination of rifampicin plus rifampicin- 
dependent antibiotic (linezolid, co-trimoxazole or 
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clindamycin) for Gram positive or a regimen without 
fluoroquinolone for Gram negative. Receiving 
suboptimal antibiotic treatment proved to be the only 
independent predictor of failure in this study[77]. 
Duration of therapy 
The duration of antibiotic treatment after DAIR 
is also matter of intense controversy. Traditionally, 
guidelines have recommended 3 months for infections 
in total hip and 6 months for total knee prosthesis[24]. 
There are however several papers questioning this 
axiom. 
Tornero et al.[77] found no relationship between 
failure and duration of treatment after a median 
duration of intravenous and oral antibiotic treatment 
of 8 days and 69 days respectively. A similar finding 
was reported by Lora-Tamayo[85] et al. in a 
randomized clinical trial including over 60 patients 
with acute staphylococcal PJI managed with DAIR. 
Patients were randomized to receive 8 weeks of 
treatment (short schedule) versus a long schedule (3 
months or 6 months for hip or knee prostheses, 
respectively) of levofloxacin plus rifampicin. They 
suggest that the short schedule could be just as 
effective as a longer standard treatment for THA but 
some doubt persisted over its value for TKA[85]. 
Despite some conflicting evidence, extending therapy 
for 3 months seems to be sufficient for the majority of 
cases[60, 61, 77, 81, 83]. Although many physicians 
rely on C-reactive protein serial measurements to 
guide antibiotic discontinuation, this practice has 
been found to be unreliable and not predictive of 
failure and should therefore be discouraged[85-87]. 
Failure and treatment options 
In an effort to accurately predict the probability 
of success thus helping decide on the best course of 
treatment, some authors have tried to come out with 
prognostic preoperative scores such as the KLIC-score 
[22]. This score based on patient and index surgery 
specific variables has been shown to be highly 
predictive especially in the lower and upper ends of 
the spectrum [14, 22, 88, 89]. While, data on 
prospectively applying these tools for 
decision-making before DAIR is undertaken is still 
missing, it seems natural to rely on it for 
reconsideration after initial treatment failure. 
Failures can be broadly divided into early 
failures where DAIR fails to achieve infection control 
and late failures where infection relapses after 
apparent good initial response. In both cases, 
recurrent PJI after DAIR procedures is most often due 
to identical microorganisms suggesting treatment 
failed to eradicate infection effectively [12, 17, 18, 21, 
22, 27].  
 
Table 2. Summary of selected recent findings regarding antibiotic regimen after DAIR 
 Joint(s) Country of 
Origin 
Overall Success 
Rate 
Major finding(s) 
Aboltins et al.[35] 2011 15 THA + 2 TKA Australia 94% 
at the 2-years 
follow-up 
Exclusively GN PJI – oral ciprofloxacin in 14 cases and amoxicillin/clavulanic acid in three 
cases 
Median duration of oral antibiotic treatment was 12 months 
Vilchezet al.[81] 2011 18 THA + 35 TKA Spain 75% 
minimum 
two-year 
follow-up 
Exclusively S. aureus PJI – rifampin combination therapy in 91% of the patients. Only 4 
MRSA. 
Duration of antibiotic therapy >90days did not improve outcome 
Puhto et al.[61] 2012 55 THA + 77 TKA Finland 65% 
at the 2-years 
follow-up 
Rifampin combination(s) preferred for staphylococci and quinolones preferred for GN 
Reducing duration of treatment to 3 months (vs. 6) for TKA and 2 months (vs. 3) for THA did 
not influence outcome 
Peel et al.[60] 2013 28 THA + 15 TKA Australia 77% 
at the 2-years 
follow-up 
Exclusively MR staphylococci PJI – rifampin combination therapy in 93% of the patients 
MRSA infections and <90 days antibiotic therapy were more likely to fail 
Rodríguez-Pardo et 
al.[36] 2014 
115 THA + 57 TKA 
+ 2 other joints 
Spain 68% 
median 25-months 
follow-up 
Exclusively GN PJI – 79% (98/124) success rate in ciprofloxacin-susceptible treated with it 
41% (14/34) success rate in ciprofloxacin-resistant and 40% (6/15) success rate in 
ciprofloxacin-susceptible not treated with it 
79% (33/42) success rate in Pseudomonas PJI increased to 88% (29/33) when treated with 
ciprofloxacin 
53% (8/15) success rate in ESBL-producing Enterobacteriaceae PJI 
Median antibiotic treatment duration was 70 days 
Holmberg et al.[13] 
2015 
145 TKA Sweden 75% 
minimum 
one-year 
follow-up 
Risk of failure was 4 times higher if no rifampin used in staphylococci infections (59% vs 19%) 
Failure rate was higher in polymicrobial (9/30) and Gram negative cases (2/5) - albeit not 
statistically significant 
Large variation in duration of antibiotic treatment 
Lora-Tamayo et 
al.[85]2016 
29 THA + 24 TKA Spain 93% 
minimum 
one-year 
follow-up 
Randomized and open trial. Exclusively staphylococci acutePJI receiving 
rifampin-levofloxacin combination. 
Cure rate in the patients who completed antibiotic treatment was 22/24 (92%) in the short (8 
weeks) protocol vs. 19/20 (95%) in the long (3 and 6 months for THA and TKA respectively) 
Grossi et al.[83] 2016 35 THA + 18 TKA 
+ 23 Hemi hips 
France 79% 
minimum 
one-year 
follow-up 
Exclusively GN PJI: 35 DAIR procedures -8 (22%) failed 
Failure rate was similar whether fluoroquinolones or three month IV ß-lactams were used 
Median antibiotic treatment duration was 90 days 
DAIR -Debridement Antibiotics and Irrigation with implant Retention; TKA –Total knee arthroplasty; THA –Total hip arthroplasty; MRSA –methicillin-resistant S. aureus; 
GN –Gram negative 
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In the first clinical scenario, a repeated surgical 
debridement may be attempted although this strategy 
is highly controversial. On one hand, Vilchez et al.[81] 
found the need for a second debridement to be 
associated with failure. These results were confirmed 
in a large, retrospective multicenter study of S. aureus 
PJI (n=345) where the need of a second debridement 
was an independent variable associated with 
failure[32]. On the other hand, there are a number of 
papers that do not find the need for more than one 
unplanned debridement to be associated with worse 
outcomes[18, 21, 59]. This controversy is even more 
intricate by the fact that some centers advocate for 
standard repeated debridements every 48-72h in 
order to reduce the bacterial load regardless of clinical 
evolution. Peel et al.[60] performed protocoled 
multiple debridements and found the optimal 
number to be two or three as there was significantly 
higher risk of failure in patients with either a single or 
at least four surgical debridements.  
Recently, Moojen et al.[90] compared these two 
different strategies in the treatment of acute THA 
infection. Although it was not statistically significant, 
they did find an increased failure rate in the group of 
patients that always received multiple surgical 
debridements (10/35) as compared to the group of 
patients that received a single surgical debridement 
and only additional surgery if infectious symptoms 
persisted (4/33)[90]. Additionally, in the former 
group, new and more resistant microorganisms were 
found in subsequent debridements suggesting every 
time the wound is opened there is a risk of further 
contamination[90].  
Another treatment alternative is to proceed to 
implant removal. Although the real impact of 
previous failed DAIR on the likelihood of success 
after exchange surgery is not yet fully understood, 
most surgeons would agree that exchange surgery is 
the natural choice when facing a late infection 
relapse[3, 4, 91]. The same might be true in some cases 
of early failure, especially if significant risk factors for 
DAIR failure are present (e.g. high KLIC score, 
unfavorable microbial pathogen, etc.) as previously 
discussed.  
Future Perspectives 
Presently, duration of infection before DAIR is 
indisputably a major variable to consider as it 
correlates directly to the microbial biofilm paradigm. 
It is known that the development of a biofilm onto an 
orthopedic implant starts within the first few minutes 
and hours after exposure. There is a progressive 
maturation process and younger biofilms do seem to 
be more susceptible to (a limited number of) 
antibiotics than more mature biofilms and this is a 
major premise behind adequate case selection for 
DAIR[8]. What constitutes the difference and where 
the exact frontier is between a young susceptible 
biofilm and a more mature resistant infection is still 
undetermined. Naturally some way to differentiate 
chronic mature biofilm infections from acute cases 
where biofilm is still susceptible would be of great 
benefit. A promising research path based on 
serological detection of elevated levels of antibody to 
microbial antigens, specifically “anti-biofilm” 
antigens is underway[92, 93].  
Another potential target would be to increase 
our ability to cause biofilm disruption in vivo. 
Chlorhexidine and acetic acid are examples of such 
strategies that are already being used but they offer 
limited efficacy. Presently, rifampicin and 
ciprofloxacin to some degree are the only effective 
antibiotic therapy and alternative drug(s) are 
desperately needed. Antimicrobial peptides (ex. 
chitosan) are a new class of antibiotics with very 
interesting features. They are highly active against a 
broad spectrum of microorganisms, highly selective 
towards microorganisms and not mammalian cells, 
present fast killing even at low concentrations and 
most importantly, they have a much lower tendency 
to induce resistance[94]. If in vivo biofilm disruption 
therapy becomes real, the need for revision surgery 
would greatly diminish. 
Conclusion 
For the time being accurate case selection and 
attention to detail in every aspect of treatment such as 
rigorous surgical procedure technique and adequate 
postoperative anti-biofilm antibiotic therapy is critical 
if DAIR is to be performed. 
However, in some extreme clinical conditions, 
usually old and frail patients, DAIR may be indicated 
as a means to temporarily alleviate symptoms caused 
by planktonic bacteria leaving the biofilm during 
acute exacerbations of a chronically infected implant. 
It will not be able to eradicate biofilm and ensuing 
chronic suppressive antibiotic therapy is often 
required but sometimes this may be the lesser of two 
evils in situations where the patient is not fit to 
undergo major revision surgery. 
It is the authors belief that if appropriate 
minimal conditions are met (short duration of 
symptoms in a stable and well-fixed prosthesis with 
sound soft tissues and no sinus tract), DAIR should be 
regarded as first-line treatment choice in the vast 
majority of cases. This approach has resulted in 
successful infection eradication in 85% of cases at 
two-years minimum follow-up[95]. 
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